Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong
· Delayed Price · Currency is HKD
214.40
+5.40 (2.58%)
Jun 6, 2025, 4:08 PM HKT
Duality Biotherapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Revenue | 1,941 | 1,787 |
| Revenue Growth (YoY) | 8.66% | - |
| Cost of Revenue | 1,157 | 427.66 |
| Gross Profit | 784.67 | 1,359 |
| Selling, General & Admin | 158.69 | 62.57 |
| Research & Development | 815.38 | 559 |
| Other Operating Expenses | -2.36 | 1.06 |
| Operating Expenses | 971.71 | 622.62 |
| Operating Income | -187.04 | 736.27 |
| Interest Expense | -0.25 | -0.19 |
| Interest & Investment Income | 48.11 | 34.48 |
| Currency Exchange Gain (Loss) | 12.27 | 41.94 |
| Other Non Operating Income (Expenses) | -873.42 | -1,018 |
| EBT Excluding Unusual Items | -1,000 | -205.4 |
| Asset Writedown | -21.35 | - |
| Other Unusual Items | 7.12 | 3.15 |
| Pretax Income | -1,015 | -202.25 |
| Income Tax Expense | 35.89 | 155.26 |
| Net Income | -1,050 | -357.51 |
| Net Income to Common | -1,050 | -357.51 |
| Shares Outstanding (Basic) | 8 | 8 |
| Shares Outstanding (Diluted) | 8 | 8 |
| EPS (Basic) | -131.30 | -44.69 |
| EPS (Diluted) | -131.30 | -44.69 |
| Free Cash Flow | 281.7 | 805.05 |
| Free Cash Flow Per Share | 35.21 | 100.63 |
| Gross Margin | 40.42% | 76.06% |
| Operating Margin | -9.63% | 41.21% |
| Profit Margin | -54.11% | -20.01% |
| Free Cash Flow Margin | 14.51% | 45.06% |
| EBITDA | -183.72 | 737.75 |
| EBITDA Margin | -9.46% | 41.30% |
| D&A For EBITDA | 3.32 | 1.48 |
| EBIT | -187.04 | 736.27 |
| EBIT Margin | -9.63% | 41.21% |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.